Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinephrine spray on the major papilla to prevent post-ERCP pancreatitis
IRCT20200825048515N35Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epinephrine in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Frequency of cannulation and Incidence of post-ERCP pancreatitis. Started Jun 2021; status: completed.
02
Drugs
epinephrine
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20200825048515N35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N35.